Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of JNJ-78278343 in advanced prostate cancer
NL-OMON60885Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of pasritamig in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started Aug 2021; status: active, not recruiting.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON60885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60885.